Other than the obvious......test failure, insider selling, etc...
one of the things I would consider is not securing a partner by the end of the year. I understand the potential for greater PPS rise by going it alone, however, if corporate potential is as I currently surmise, I would expect a major player to make a favorable offer. If big-pharma doesn't see great potential and isn't willing to invest..... possibly I should reevaluate. Thanks for asking. Your take?
News 
Market Data 
Discover 
